AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34551229 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebentafusp
Number of subjects: 378
Study 34551229 — intervention group
Group type: COMPARATOR
Intervention: Control (investigator's choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine)
Number of subjects: 378
Study 35799239 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose monotherapy
Number of subjects: 187
Study 35799239 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 187
Study 35799239 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii monotherapy
Number of subjects: 187
Study 35372900 — intervention group
Group type: EXPERIMENTAL
Intervention: ISD/HY
Number of subjects: 17
Study 35372900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 35489037 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% chlorhexidine gluconate vaginal preparation
Number of subjects: 240
Study 35489037 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 240
Study 35145853 — intervention group
Group type: EXPERIMENTAL
Intervention: SP‐TCM training
Number of subjects: 0
Study 35145853 — intervention group
Group type: COMPARATOR
Intervention: Traditional‐method training
Number of subjects: 0
Study 33065358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostering Changes program
Number of subjects: 26
Study 33065358 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study 36235848 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback e‐12HR application (intervention group)
Number of subjects: 286
Study 36235848 — intervention group
Group type: COMPARATOR
Intervention: Non-feedback e‐12HR application (control group)
Number of subjects: 286
Study 34022790 — intervention group
Group type: EXPERIMENTAL
Intervention: Three antihypertensive regimens for 6 months
Number of subjects: 721
Study 34022790 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 721
Study 32773308 — intervention group
Group type: COMPARATOR
Intervention: Control calf starter (CS) with conventional soybean meal (SBM) as the main source of protein (CTRL)
Number of subjects: 3
Study 32773308 — intervention group
Group type: EXPERIMENTAL
Intervention: Isonitrogenous (20% CP) CS with enzyme‐treated SBM as the main source of protein (ENZT)
Number of subjects: 3
Study 32773308 — intervention group
Group type: EXPERIMENTAL
Intervention: CS with low content of CP (10%) and no soy protein (LOCP)
Number of subjects: 3
Study 32773308 — intervention group
Group type: EXPERIMENTAL
Intervention: HICP diets (high-protein diets)
Number of subjects: 3
Study 32773308 — intervention group
Group type: EXPERIMENTAL
Intervention: ENZT diet (enzyme-treated SBM)
Number of subjects: 3
Study 34151874 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized vestibular rehabilitation plus standard canalith repositioning maneuver (CRM) for six weeks
Number of subjects: 28
Study 34151874 — intervention group
Group type: COMPARATOR
Intervention: Standard canalith repositioning maneuver (CRM) for two weeks
Number of subjects: 28
Study 34528761 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 4664
Study 34528761 — intervention group
Group type: COMPARATOR
Intervention: No LDCT screening
Number of subjects: 4664
Study 33734750 — intervention group
Group type: EXPERIMENTAL
Intervention: Not sure option: yes
Number of subjects: 2724
Study 33734750 — intervention group
Group type: COMPARATOR
Intervention: Not sure option: no
Number of subjects: 2724
Study 32491006 — intervention group
Group type: EXPERIMENTAL
Intervention: C30 (30% load)
Number of subjects: 20
Study 32491006 — intervention group
Group type: EXPERIMENTAL
Intervention: C60 (60% load)
Number of subjects: 20
Study 32491006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 33559212 — intervention group
Group type: EXPERIMENTAL
Intervention: Body shape pattern group (selection based on observed body shape indices, BMI, and sex)
Number of subjects: 162
Study 33559212 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional dorsogluteal injection)
Number of subjects: 162
Study 33559212 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric indices group (selection based on BMI, waist circumference, and ASIS-IT)
Number of subjects: 162
Study 32694638 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 103
Study 35759049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counseling plus logotherapy (n=46)
Number of subjects: 90
Study 35759049 — intervention group
Group type: COMPARATOR
Intervention: Nutrition counseling alone (n=44)
Number of subjects: 90
Study 34176795 — intervention group
Group type: EXPERIMENTAL
Intervention: Home safety supervisory program (HSSP)
Number of subjects: 0
Study 34176795 — intervention group
Group type: COMPARATOR
Intervention: Teaching on child care (Control)
Number of subjects: 0
Study 32041859 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous osteoperiosteal cylinder graft transplantation
Number of subjects: 70
Study 32041859 — intervention group
Group type: COMPARATOR
Intervention: Autologous osteochondral transplantation
Number of subjects: 70
Study 35902298 — intervention group
Group type: EXPERIMENTAL
Intervention: Carryover voice therapy using carryover strategies
Number of subjects: 53
Study 35902298 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional voice therapy with no emphasis on generalizing process
Number of subjects: 53
Study 35902298 — intervention group
Group type: EXPERIMENTAL
Intervention: Carryover voice therapy
Number of subjects: 53
Study 35902298 — intervention group
Group type: COMPARATOR
Intervention: Controls (eight-week non-therapy period)
Number of subjects: 53
Study 32751170 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 g of rapeseed protein isolate
Number of subjects: 20
Study 32751170 — intervention group
Group type: COMPARATOR
Intervention: Soy protein isolate (control)
Number of subjects: 20
Study 36096353 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Facebook group (n = 60)
Number of subjects: 119
Study 36096353 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional-led Facebook group (n = 59)
Number of subjects: 119
Study 36096353 — intervention group
Group type: COMPARATOR
Intervention: Both conditions (Standard and Professional-led)
Number of subjects: 119
Study 33947346 — intervention group
Group type: EXPERIMENTAL
Intervention: TMCP approach used by clinicians
Number of subjects: 8198
Study 33947346 — intervention group
Group type: EXPERIMENTAL
Intervention: AAC + TMCP
Number of subjects: 8198
Study 33947346 — intervention group
Group type: COMPARATOR
Intervention: AAC only
Number of subjects: 8198
Study 32105268 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognan (citicoline), 100 mg in 1 ml, taken orally for 30 days (daily dosage of 0.5 g).
Number of subjects: 38
Study 32105268 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no medication).
Number of subjects: 38
Study 36224294 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 0
Study 36224294 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin 5 mg
Number of subjects: 0
Study 33409777 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 incorporating selected morphological and clinical features
Number of subjects: 205
Study 33409777 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 incorporating selected texture and clinical features
Number of subjects: 205
Study 33409777 — intervention group
Group type: COMPARATOR
Intervention: High-grade serous carcinoma (HGSC)
Number of subjects: 205
Study 33409777 — intervention group
Group type: COMPARATOR
Intervention: Both models
Number of subjects: 205
Study 35990057 — intervention group
Group type: EXPERIMENTAL
Intervention: taVNS combined with electroacupuncture (8 weeks, 3 sessions per week for taVNS; 8 weeks, twice per day for electroacupuncture)
Number of subjects: 60
Study 35990057 — intervention group
Group type: COMPARATOR
Intervention: citalopram (8 weeks, 40 mg/day)
Number of subjects: 60
Study 35990057 — intervention group
Group type: COMPARATOR
Intervention: citalopram
Number of subjects: 60
Study 33861432 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplement (500 mg daily for 12 weeks)
Number of subjects: 66
Study 33861432 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 66
Study 32748072 — intervention group
Group type: EXPERIMENTAL
Intervention: Charisma resin composite restorations
Number of subjects: 40
Study 32748072 — intervention group
Group type: COMPARATOR
Intervention: Charisma Classic resin composite restorations
Number of subjects: 40
Study 32305184 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating heart simulator training
Number of subjects: 60
Study 32305184 — intervention group
Group type: COMPARATOR
Intervention: Nonbeating heart simulator training
Number of subjects: 60
Study 32474935 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switching (PS) implants
Number of subjects: 18
Study 32474935 — intervention group
Group type: COMPARATOR
Intervention: Platform-matching (PM) implants
Number of subjects: 18
Study 35921357 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 100
Study 35921357 — intervention group
Group type: COMPARATOR
Intervention: IVF (In Vitro Fertilization)
Number of subjects: 100
Study 35921357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effective profile of surgery
Number of subjects: 100
Study 35921357 — intervention group
Group type: COMPARATOR
Intervention: Cost-effective profile of IVF
Number of subjects: 100
Study 32540986 — intervention group
Group type: EXPERIMENTAL
Intervention: DOSE HPV intervention (7-session program including provider education, communication training, data feedback, and tailored systems change)
Number of subjects: 5
Study 32540986 — intervention group
Group type: EXPERIMENTAL
Intervention: DOSE HPV intervention
Number of subjects: 5
Study 33503045 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial behavior intervention
Number of subjects: 0
Study 33503045 — intervention group
Group type: COMPARATOR
Intervention: Self-focused behavior
Number of subjects: 0
Study 33503045 — intervention group
Group type: COMPARATOR
Intervention: Neutral behavior
Number of subjects: 0
Study 32086901 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray allergen blocker combined with azelastine hydrochloride nasal spray
Number of subjects: 84
Study 32086901 — intervention group
Group type: COMPARATOR
Intervention: Azelastine hydrochloride nasal spray
Number of subjects: 84
Study 33621541 — intervention group
Group type: EXPERIMENTAL
Intervention: ticagrelor plus aspirin (DAPT)
Number of subjects: 3486
Study 33621541 — intervention group
Group type: COMPARATOR
Intervention: ticagrelor plus matching placebo (SAPT)
Number of subjects: 3486
Study 33621541 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided DES implantation
Number of subjects: 3486
Study 33621541 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided DES implantation
Number of subjects: 3486
Study 36327527 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) Q3W for four cycles with once-daily cabozantinib (40 mg), then nivolumab (240 mg) Q2W plus once-daily cabozantinib (40 mg)
Number of subjects: 50
Study 35597972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy/Motivational Interviewing (CBT/MI) intervention, administered in six sessions over 3 months.
Number of subjects: 20
Study 32141054 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption (3 cups after cesarean)
Number of subjects: 103
Study 32141054 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 103
Study 33574070 — intervention group
Group type: EXPERIMENTAL
Intervention: reconstructed chest radiograph (r-CXR)
Number of subjects: 300
Study 33574070 — intervention group
Group type: COMPARATOR
Intervention: high-resolution CT (HRCT)
Number of subjects: 300
Study 33574070 — intervention group
Group type: EXPERIMENTAL
Intervention: r-CXR
Number of subjects: 300
Study 33574070 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 300
Study 33574070 — intervention group
Group type: EXPERIMENTAL
Intervention: r-CXR and HRCT
Number of subjects: 300
Study 32706937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib 600-mg tablet
Number of subjects: 94
Study 32706937 — intervention group
Group type: COMPARATOR
Intervention: Ribociclib 600-mg capsule
Number of subjects: 94
Study 32706937 — intervention group
Group type: COMPARATOR
Intervention: Ribociclib intravenous infusion 150 mg
Number of subjects: 94
Study 32706937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib oral administration
Number of subjects: 94
Study 32706937 — intervention group
Group type: COMPARATOR
Intervention: Ribociclib 600-mg tablet and capsule
Number of subjects: 94
Study 36162958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulisation using NHF
Number of subjects: 33
Study 36162958 — intervention group
Group type: COMPARATOR
Intervention: Nebulisation using JN
Number of subjects: 33
Study 34086067 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX04 (3 mg/kg intravenous infusion)
Number of subjects: 208
Study 34086067 — intervention group
Group type: COMPARATOR
Intervention: HLX04 and reference bevacizumab
Number of subjects: 208
Study 32785654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint interval training or moderate-intensity continuous training for two weeks
Number of subjects: 54
Study 32785654 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary, no exercise training)
Number of subjects: 54
Study 36121700 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with everolimus-eluting stents
Number of subjects: 880
Study 36121700 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 880
Study 33287685 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT), 4 sessions of 1 hour
Number of subjects: 60
Study 33287685 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 60
Study 36219596 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised self-management support co-designed with participants
Number of subjects: 45
Study 36219596 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 45
Study 34134828 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐cycloserine augmented ERP
Number of subjects: 161
Study 34134828 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo augmented ERP
Number of subjects: 161
Study 33106696 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care
Number of subjects: 61
Study 33106696 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 61
Study 34580975 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 23
Study 34580975 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 1 mg
Number of subjects: 23
Study 34529768 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA plus arsenic trioxide (ATO)
Number of subjects: 161
Study 34529768 — intervention group
Group type: COMPARATOR
Intervention: ATRA chemotherapy
Number of subjects: 161
Study 33284672 — intervention group
Group type: EXPERIMENTAL
Intervention: Body diversity intervention
Number of subjects: 160
Study 33284672 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-ideal intervention
Number of subjects: 160
Study 33284672 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 32375840 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugira Muryango
Number of subjects: 541
Study 35123070 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide acetate pen injector
Number of subjects: 45
Study 35580203 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine manual aspiration thrombectomy
Number of subjects: 2869
Study 34943854 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU ablation of primary cancer followed by modified radical mastectomy
Number of subjects: 48
Study 34943854 — intervention group
Group type: COMPARATOR
Intervention: Control group (modified radical mastectomy only)
Number of subjects: 48
Study 34943854 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU group
Number of subjects: 48
Study 36152268 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-HBc level <325 IU/ml
Number of subjects: 136
Study 36152268 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-HBc level ≥325 IU/ml
Number of subjects: 136
Study 36152268 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anti-HBc <325 IU/ml with HBsAg >3008 IU/ml
Number of subjects: 136
Study 36152268 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anti-HBc <325 IU/ml with HBcrAg ≥1790 U/ml
Number of subjects: 136
Study 33821793 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological glucocorticoid exposure
Number of subjects: 10
Study 33821793 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal from glucocorticoid exposure
Number of subjects: 10
Study 35513720 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS‐transspinal paired with locomotor training
Number of subjects: 8
Study 35513720 — intervention group
Group type: EXPERIMENTAL
Intervention: transspinal‐TMS paired with locomotor training
Number of subjects: 8
Study 33406892 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (5 days a week for 8 weeks, consisting of six sets of 30 breaths per day with a training load ≥50% of maximal inspiratory pressure)
Number of subjects: 39
Study 33406892 — intervention group
Group type: COMPARATOR
Intervention: Control group (only received the educational program)
Number of subjects: 39
Study 33406892 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 39
Study 33406892 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory muscle training and Control group
Number of subjects: 39
Study 34247614 — intervention group
Group type: EXPERIMENTAL
Intervention: Community empowerment intervention including a community-led drop-in-center, venue-based peer education, condom distribution, HIV testing, peer service navigation, sensitivity trainings, and text messages to promote engagement.
Number of subjects: 339
Study 34247614 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at the Shikamana drop-in-center.
Number of subjects: 339
Study 34247614 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at a family planning-related workshop.
Number of subjects: 339
Study 35696397 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Gastrointestinal Disorders (FGIDs)
Number of subjects: 860
Study 35696397 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Dyspepsia (FD)
Number of subjects: 860
Study 35696397 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Heartburn
Number of subjects: 860
Study 35696397 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Bloating
Number of subjects: 860
Study 35696397 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping disorders
Number of subjects: 860
Study 35696397 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial alarm symptoms
Number of subjects: 860
Study 35696397 — intervention group
Group type: EXPERIMENTAL
Intervention: Victimization
Number of subjects: 860
Study 34413443 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection by trained dogs in laboratory conditions
Number of subjects: 2
Study 34413443 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection by trained dogs in semi-field conditions
Number of subjects: 2
Study 34413443 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection by trained dogs in standardized field conditions
Number of subjects: 2
Study 32114513 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with bevacizumab
Number of subjects: 227
Study 36258168 — intervention group
Group type: EXPERIMENTAL
Intervention: Padres Preparados, Jóvenes Saludables program (8 weekly sessions of 2.5 hours each)
Number of subjects: 147
Study 36258168 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed-treatment)
Number of subjects: 147
Study 36258168 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' sugar-sweetened beverage (SSB) intake
Number of subjects: 147
Study 36258168 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' fast food intake
Number of subjects: 147
Study 34019540 — intervention group
Group type: EXPERIMENTAL
Intervention: Free distribution of essential medicines (n = 395)
Number of subjects: 786
Study 34019540 — intervention group
Group type: COMPARATOR
Intervention: Usual medicine access (n = 391)
Number of subjects: 786
Study 32141343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ateos
Number of subjects: 48
Study 32141343 — intervention group
Group type: COMPARATOR
Intervention: FlexTouch
Number of subjects: 48
Study 36030464 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD
Number of subjects: 849
Study 36030464 — intervention group
Group type: COMPARATOR
Intervention: TV-ICD
Number of subjects: 849
Study 33049918 — intervention group
Group type: EXPERIMENTAL
Intervention: SVF combined with β‐TCP
Number of subjects: 0
Study 33049918 — intervention group
Group type: COMPARATOR
Intervention: β‐TCP alone (Control)
Number of subjects: 0
Study 36129708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic interventions including earplugs, eye mask, aromatherapy, and postponed morning medication and vital sign measurement rounds.
Number of subjects: 374
Study 36129708 — intervention group
Group type: COMPARATOR
Intervention: Control group received usual care without nonpharmacologic interventions.
Number of subjects: 374
Study 36129708 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups reported main sleep-disturbing factors: noises, pain, toilet visits, and being awakened by hospital staff.
Number of subjects: 374
Study 36129708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with postponed vital sign checks and medication rounds.
Number of subjects: 374
Study 33635604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function (measured by Mini Mental State Exam)
Number of subjects: 0
Study 33635604 — intervention group
Group type: EXPERIMENTAL
Intervention: Independence of self-feeding
Number of subjects: 0
Study 33635604 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse support
Number of subjects: 0
Study 33635604 — intervention group
Group type: EXPERIMENTAL
Intervention: General self-care capacity
Number of subjects: 0
Study 33635604 — intervention group
Group type: EXPERIMENTAL
Intervention: Appetite the week before
Number of subjects: 0